|Mr. Thomas K. Equels Esq., M.S., J.D.||Exec. Vice Chairman, CEO & Pres||778.27k||N/A||64|
|Mr. Adam Pascale CPA||CFO & Chief Accounting Officer||222.8k||N/A||69|
|Dr. David R. Strayer M.D.||Chief Scientific Officer & Medical Director||316.81k||N/A||71|
|Mr. Wayne S. Springate||Sr. VP of Operations||N/A||N/A||46|
|Ann Marie E. Coverly||Director of Admin. & HR and Deputy Investor Relations Coordinator||N/A||N/A||N/A|
Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The companys approved products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of sexually transmitted disease infection; and Ampligen, a product approved for sale in Argentina for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, renal cell carcinoma, and malignant melanoma; Alferon N Injection for the treatment of various categories of genital warts; and Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon for the treatment of pandemic influenza, seasonal influenza, and other viruses. The company was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.
Hemispherx Biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.